Kim, Seok Jin; Kim, Jeeyong; Cho, Yunjung; Seo, Bo Kyoung; Kim, Byung Soo
Japanese journal of clinical oncology
2007May ; 37 ( 5 ) :382-4.
PMID : 17538191
ÀúÀÚ »ó¼¼Á¤º¸
Kim, Seok Jin -
Kim, Jeeyong -
Cho, Yunjung -
Seo, Bo Kyoung -
Kim, Byung Soo -
ABSTRACT
Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m(2) intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1-4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.
bortezomib, cyclophosphamide, plasma cell leukemia, multiple myeloma
MESH
Adult, Antineoplastic Agents/administration & dosage, Antineoplastic Agents, Alkylating/administration & dosage, Antineoplastic Agents, Hormonal/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Boronic Acids/administration & dosage, Bortezomib, Cyclophosphamide/administration & dosage, Dexamethasone/administration & dosage, Humans, Leukemia, Plasma Cell/*drug therapy, Male, Pyrazines/administration & dosage
¸µÅ©